evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,733 questions · 1,794 findings · 326 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 243 · 13.5%GRADE not reported 96 · 5.4%Very low 597 · 33.3%Low 506 · 28.2%Moderate 303 · 16.9%High 49 · 2.7%

Summary of findings table ‐ Stem Cell vs placebo or control

Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease

Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Potent vs moderate‐potency topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).

1 finding from 1 review

Very potent vs potent topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema

Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).

1 finding from 1 review

Twice daily or more vs once daily topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema

Twice daily or more showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with once daily topical corticosteroid (moderate certainty).

1 finding from 1 review

Twice daily or more vs once daily topical corticosteroid

Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema

Twice daily or more showed no clear difference in patient‐reported symptoms of eczema: PGA (number with cleared or… compared with once daily topical corticosteroid (low certainty).

1 finding from 1 review

Potent vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema

Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Potent vs moderate‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema

Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Intervention not reported

Short cephalomedullary nail (34 studies; 6437 participants)a · older adults (> 60 years of age) with extracapsular hip fractures

It is very uncertain whether the intervention changes short cephalomedullary nail (34 studies; 6437 participants)a (very low certainty).

1 finding from 1 review

Intervention not reported

Short cephalomedullary nail (33 studies; 5380 participants)a · older adults (> 60 years of age) with extracapsular hip fractures

It is very uncertain whether the intervention changes short cephalomedullary nail (33 studies; 5380 participants)a (very low certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

QoL · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

QoL · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 26‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review